Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

861 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia.
Marcucci G, Byrd JC, Dai G, Klisovic MI, Kourlas PJ, Young DC, Cataland SR, Fisher DB, Lucas D, Chan KK, Porcu P, Lin ZP, Farag SF, Frankel SR, Zwiebel JA, Kraut EH, Balcerzak SP, Bloomfield CD, Grever MR, Caligiuri MA. Marcucci G, et al. Among authors: byrd jc. Blood. 2003 Jan 15;101(2):425-32. doi: 10.1182/blood-2002-06-1899. Epub 2002 Aug 22. Blood. 2003. PMID: 12393493 Free article. Clinical Trial.
Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein.
Aron JL, Parthun MR, Marcucci G, Kitada S, Mone AP, Davis ME, Shen T, Murphy T, Wickham J, Kanakry C, Lucas DM, Reed JC, Grever MR, Byrd JC. Aron JL, et al. Among authors: byrd jc. Blood. 2003 Jul 15;102(2):652-8. doi: 10.1182/blood-2002-12-3794. Epub 2003 Mar 20. Blood. 2003. PMID: 12649137 Free article.
Advances in the therapy of chronic lymphocytic leukemia.
Johnson AJ, Mone AP, Abhyankar V, Byrd JC. Johnson AJ, et al. Among authors: byrd jc. Curr Opin Hematol. 2003 Jul;10(4):297-305. doi: 10.1097/00062752-200307000-00008. Curr Opin Hematol. 2003. PMID: 12799536 Review.
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.
Byrd JC, Rai K, Peterson BL, Appelbaum FR, Morrison VA, Kolitz JE, Shepherd L, Hines JD, Schiffer CA, Larson RA. Byrd JC, et al. Blood. 2005 Jan 1;105(1):49-53. doi: 10.1182/blood-2004-03-0796. Epub 2004 May 11. Blood. 2005. PMID: 15138165 Free article.
Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
Eisenbeis CF, Grainger A, Fischer B, Baiocchi RA, Carrodeguas L, Roychowdhury S, Chen L, Banks AL, Davis T, Young D, Kelbick N, Stephens J, Byrd JC, Grever MR, Caligiuri MA, Porcu P. Eisenbeis CF, et al. Among authors: byrd jc. Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6101-10. doi: 10.1158/1078-0432.CCR-04-0525. Clin Cancer Res. 2004. PMID: 15447996 Clinical Trial.
861 results